Clinical Trial to Evaluate the Efficacy of Intracavernosal Infusion of PRP vs PPP for the Erectile Dysfunction. (PRePED)

A Randomized, Double-blind Controlled Trial to Evaluate the Efficacy of Intracavernosal Infusion of Platelet Rich Plasma Against Platelet Poor Plasma in the Treatment of Vasculogenic Erectile Dysfunction.

Randomized, double-blind clinical trial to evaluate efficacy, feasibility and safety with two groups in a 1:1 ratio; where the control group corresponds to patients who will receive Platelet Poor plasma and an experimental group where patients will receive Platelet Rich Plasma, both collected by apheresis.

Study Overview

• Status: Unknown
• Conditions: Erectile Dysfunction
• Intervention / Treatment: Drug: PRP; Drug: PPP

Detailed Description

Patients treated in the urology department of the Hospital Universitario Puerta de Hierro Majadahonda, are eligible and will be offered the participation in this clinical trial.

The target populations are patients who presented erectile dysfunction for at least 6 months with an IIEF-EF between 5 and 16 points. They will be pre-screened for eligibility.

The patient must complete the informed consent form (ICF) process and sign and date the informed consent form prior to participation in this study, including completion of any non-standard-of- care procedures required for this clinical Investigation.

If the patient meets the inclusion criteria and additionally meet with the apheresis procedures, the patient wil be included in the study.

The study include two phases. In the first phase, the patient will be randomized to PPP or PPP. In the second phase, according with the score IIEF-EF (responder or non responder), the patient will receive PRP.

With the responders patients, an open phase with PDE5-Is is initiated. The patient will use phosphodiesterase 5 inhibitors (PDE5-Is) at maximum tolerated doses according with the Summary Product of characteristics.

With the no responders patients, there will be two options:

If the non-responder patient was in treatment with PRP during the firs phase, the patient will continue with the procedures of visits 11a and 12a.

If the non-responder patient was in treatment with PPP, the patient will start the second phase of treatment with PRP and will continue with the procedures of this treatment phase.

• Study Type: Interventional
• Enrollment (Anticipated): 52
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Juan Ignacio Martínez-Salamanca, MD, PhD; Phone Number: +34 91 191 71 95; Email: jims@lyxurologia.com
• Study Contact Backup: Name: Gustavo Centeno, MD, PhD; Phone Number: 91 191 6026; Email: gustavoadolfo.centeno@salud.madrid.org

Study Locations

• Spain
  • Madrid
    • Majadahonda, Madrid, Spain, 28222
      • Recruiting
      • Puerta de Hierro University Hospital
      • Contact: Gustavo Centeno, MD; Phone Number: 91 191 6026; Email: gustavoadolfo.centeno@salud.madrid.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Signed an ethics committee-reviewed and approved informed consent form.
• Subjects must meet all inclusion criteria to be eligible for study enrollment.
• Men between 40 and 75 years old, with a relationship of more than 6 months of duration.
• Erectile dysfunction for at least 6 months with an IIEF-EF (while using the higher tolerated dose of PDE5-Is) between 5 and 16 points, inclusive.
• Erectile dysfunction of vascular origin. In case of clinical doubt or incongruence, a Nocturnal Penile Tumescence and Rigidity Test (NPTR) will be performed. In this case, criteria inclusion is having no event in the night with a penile rigidity (tip) of ≥70% during ≥5min.
• Subjects agree to attempt vaginal intercourse at least 4 times every month after the end of the treatment and agree to document the outcome using the Sexual Encounter Profile (SEP) and the Erection Hardness Score (EHS).
• Commitment not to use other treatment for ED during the study (herbal, topical, intraurethral, intracavernosal, etc.).
• Commitment to completing the rest of the questionnaires and other measurement instruments during the study phase.
• Willingness and ability to comply with study procedures, other measurements instruments and visit schedules and able to follow oral and written instructions.

Exclusion Criteria:

• Documented psychogenic erectile dysfunction (with NPTR test: at least one event in the night with a penile rigidity (tip) of ≥70% during ≥5min).
• Erectile dysfunction of neurogenic origin (radical prostatectomy, pelvic surgery, spinal cord injury, multiple sclerosis, diabetes mellitus is not included unless documented diabetic neuropathy).
• Some other current sexual dysfunction (premature ejaculation, etc.).
• Prior implant of penile prosthesis or other penile surgeries different to circumcision, frenuloplasty or condyloma removal.
• Previous history of penile fracture, Peyronie's disease or priapism.
• History of radical prostatic or bladder surgery (radical cystectomy or prostatectomy).
• Previous radiation to pelvis.
• History of symptomatic hypogonadism (testosterone level <346ng/dl) not treated. If treated hypogonadism, testosterone levels non-stable for at least 3 months.
• Major hematologic, renal, or hepatic abnormalities.
• Severe decompensated cardiac and vascular insufficiency, or critical coronary heart disease.
• Poorly controlled hypertension or diabetes mellitus (HbA1c >12%).
• Recent (within previous six months of the inclusion) stroke or myocardial infarction.
• Active peptic ulcer disease.
• Neoplasm of any origin in active treatment or active progression.
• History of psychiatric pathology (depressive syndrome, schizophrenia, bipolar disorder).
• History of alcohol abuse (More than 7 alcohol drink units a week or more than 3 per occasion) or drug abuse (any drug consumption different to alcohol or tobacco, used more than three times per month).
• Treatment with oral anticoagulants (dicoumarin or by-products) or antiandrogens.
• Active treatment as nitric oxide (NO) donor drugs.
• Prior positive serology to HBsAg, HCV (by genomic test), HIV-1/2, syphilis.
• Thrombopenia less than 100 x 109 / L.
• Anemia (Hemoglobin <13 g/dl).
• Poor venous access or any other circumstance that preclude an apheresis procedure.
• Lack of sexual practices in recent months (less than 4 attempts in the last three months).
• Lack of commitment on the part of the patient to attend the tests requested.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment Arm; Intracavernosal infusion of Platelet Rich Plasma	Drug: PRP; Platelet Rich Plasma (PRP) is an autologous blood component derivate from the own patient blood, with a high concentration in platelets. The liquid fraction obtained after the soft centrifugation of Whole Blood (WB) collected with anticoagulant, in a way that most of the red cells and leukocytes are sedimented and removed, but most of the platelets are kept in the supernatant plasma. The platelet concentration in PRP is not well defined.
Active Comparator: Control Arm; Intracavernosal infusion of Platelet Poor Plasma	Drug: PPP; PPP is the liquid fraction obtained after the hard centrifugation of WB collected with any anticoagulant. PPP does not contain cells. (Hematocrit lower than 1% and leukocytes below 1 x 109/L) x but contains WB proteins (including clotting factors), ions, microelements and water. PPP can be also being collected using an apheresis technique.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference of increments between PRP and PPP treatment assessed by IIEF scale	Difference of increments between both treatment groups assesed by International Index Erectile Function (IIEF) scale (referred to the investigator's study as mean PRP V9(PT)IIEF-EF - V3IIEF-EF vs mean PPP V9(PT)IIEF-EF - V3IIEF-EF) after 4 weeks of the end of the treatment.	28 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of adverse events related with the use of PRP/PPP	Incidence of infusion related Adverse Events (AEs) and cumulative of incidence of Serious Adverse Events (SAEs) during the clinical trial.	28 weeks
Synergic efficcacy of PRP and PDE5 inhibitors	Assessment of the synergic efficacy of PRP treatment on the therapeutic response to oral administration of PDE5 inhibitors by the IIEF.	28 weeks
Concentration of cytokines and growth factors in the PRP and PPP	Concentration of cytokines and growth factors concentration in the PRP and PPP of each patient and their relationship with the clinical response to PRP assessed by IIEF.	28 weeks

Collaborators and Investigators

• Sponsor: Puerta de Hierro University Hospital
• Investigators: Principal Investigator: Juan Martinez-Salamanca, Md, PhD, Urologist

Study record dates

Study Major Dates

• Study Start (Actual): February 10, 2020
• Primary Completion (Anticipated): February 28, 2022
• Study Completion (Anticipated): August 31, 2022

Study Registration Dates

• First Submitted: July 16, 2020
• First Submitted That Met QC Criteria: August 4, 2020
• First Posted (Actual): August 6, 2020

Study Record Updates

• Last Update Posted (Actual): August 6, 2020
• Last Update Submitted That Met QC Criteria: August 4, 2020
• Last Verified: August 1, 2020

More Information

Terms related to this study

• Keywords: Platelet Rich Plasma; Platelet Poor Plasma
• Additional Relevant MeSH Terms: Mental Disorders; Sexual Dysfunctions, Psychological; Sexual Dysfunction, Physiological; Erectile Dysfunction
• Other Study ID Numbers: PRePED

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No